Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis

Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101604. doi: 10.1016/j.clinre.2020.101604. Epub 2021 Jan 14.

Authors

Natasha Klemm¹, Roberto Trasolini², Daljeet Chahal², Fergal Donnellan²

Affiliations

¹ Internal Medicine Resident, University of British Columbia, 319-630 Broadway East, Vancouver, BC, V5T 0J1, Canada. Electronic address: nklemm@alumni.ubc.ca.
² University of British Columbia, Division of Gastroenterology, Gordon and Leslie Diamond Health Centre, Vancouver General Hospital, 5153-2775 Laurie St., Vancouver, V5Z 1M9, BC, Canada.

PMID: 33454238
DOI: 10.1016/j.clinre.2020.101604

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Colitis* / chemically induced
Colitis* / drug therapy
Humans
Immune Checkpoint Inhibitors / adverse effects
Infliximab / adverse effects
Steroids / adverse effects

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
Steroids
vedolizumab
Infliximab